The Fort Worth Press - Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up

USD -
AED 3.672505
AFN 64.502368
ALL 81.998222
AMD 357.803769
ANG 1.790403
AOA 918.000351
ARS 1559.243988
AUD 1.491024
AWG 1.8025
AZN 1.697591
BAM 1.782854
BBD 2.012735
BDT 124.411466
BGN 1.77347
BHD 0.377107
BIF 3003.463993
BMD 1
BND 1.288879
BOB 11.707704
BRL 5.899
BSD 0.999385
BTN 93.383593
BWP 14.117915
BYN 2.997958
BYR 19600
BZD 2.009818
CAD 1.431095
CDF 2285.00014
CHF 0.842915
CLF 0.025574
CLP 1006.490009
CNY 6.667797
CNH 6.668405
COP 3354.71
CRC 444.296568
CUC 1
CUP 23.984575
CVE 100.51779
CZK 22.22175
DJF 177.949763
DKK 6.802565
DOP 60.418499
DZD 137.053072
EGP 53.820098
ERN 15
ETB 164.020438
EUR 0.91005
FJD 2.28525
FKP 0.76038
GBP 0.760375
GEL 2.590602
GGP 0.76038
GHS 11.732317
GIP 0.76038
GMD 73.499493
GNF 8859.697901
GTQ 7.637401
GYD 209.002981
HKD 7.844715
HNL 26.862474
HRK 6.831965
HTG 131.020966
HUF 335.920292
IDR 18253
ILS 3.282095
IMP 0.76038
INR 93.28535
IQD 1514.984389
IRR 1933164.496166
ISK 124.679944
JEP 0.76038
JMD 158.502846
JOD 0.709056
JPY 159.949498
KES 130.060512
KGS 87.449537
KHR 4071.103008
KMF 448.999585
KPW 900.00035
KRW 1328.189719
KWD 0.31162
KYD 0.832836
KZT 444.440393
LAK 22515.053033
LBP 89590.84067
LKR 332.58429
LRD 167.887437
LSL 17.179374
LTL 2.95274
LVL 0.60489
LYD 6.463111
MAD 9.953508
MDL 18.347645
MGA 4544.315048
MKD 55.964687
MMK 2099.801407
MNT 3600.814049
MOP 8.076574
MRU 40.612196
MUR 46.840266
MVR 15.416238
MWK 1732.793079
MXN 18.845105
MYR 4.113204
MZN 63.915562
NAD 17.179061
NGN 1351.659682
NIO 36.77352
NOK 9.693335
NPR 149.412703
NZD 1.80985
OMR 0.384501
PAB 0.999385
PEN 3.411744
PGK 4.495877
PHP 63.690193
PKR 276.292258
PLN 4.01981
PYG 6255.270079
QAR 3.643308
RON 4.864696
RSD 107.053982
RUB 81.823857
RWF 1478.922348
SAR 3.751382
SBD 8.137041
SCR 13.883305
SDG 601.50065
SEK 10.14478
SGD 1.289585
SHP 0.757117
SLE 22.795018
SLL 20969.503664
SOS 571.095199
SRD 37.384497
STD 20697.981008
STN 22.333535
SVC 8.744046
SYP 13002.000337
SZL 17.176326
THB 33.896501
TJS 9.188906
TMT 3.5
TND 3.026701
TOP 2.40776
TRY 50.46722
TTD 6.7815
TWD 32.936502
TZS 2655.017981
UAH 45.116247
UGX 4186.987794
UYU 40.602566
UZS 12002.151381
VES 916.62795
VND 25755
VUV 120.949122
WST 2.823281
XAF 596.953744
XAG 0.022206
XAU 0.000268806004
XCD 2.70255
XCG 1.801044
XDR 0.707052
XOF 596.953744
XPF 108.71765
YER 236.550276
ZAR 17.251035
ZMK 9001.198647
ZMW 20.525699
ZWL 321.999592
SSP 5879.599296
MXV 2.113026
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up
Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up

Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up

  • Announces shareholder-focused actions reflecting management's belief that the Company's common stock is undervalued
  • Share repurchases to resume under the $5.0 million program, with approximately $3.85 million remaining available
  • Insiders commit to a 12-month lock-up on all shares of the Company's common stock they hold

Text size:

CHICAGO, IL / ACCESS Newswire / November 19, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced two shareholder-focused actions: the Company intends to resume open-market repurchases under its $5.0 million share repurchase program, and its executive officers and members of its Board of Directors have agreed to a 12-month lock-up on all shares of the Company's common stock they hold. As a result, the Company intends to repurchase its shares at the same time as its leadership has committed not to sell.

Share Repurchase Program Resumes

The Company intends to resume repurchases under the $5.0 million program authorized by its Board of Directors on June 26, 2026. To date, the Company has repurchased a total of 255,600 shares (5,112,000 pre-split) for approximately $1.15 million, with approximately $3.85 million remaining available under the program.

Repurchases may be made from time to time in the open market, in accordance with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. The timing and amount of any repurchases will depend on market conditions and other factors, and the program may be suspended or discontinued at any time.

Insiders Commit to a 12-Month Lock-Up

The Company's executive officers and members of its Board of Directors have agreed not to sell or otherwise dispose of the shares of the Company's common stock they hold for a period of 12 months, aligning the interests of the Company's leadership directly with those of its shareholders.

CEO Commentary

Greg Siokas, CEO of Cosmos Health, stated: "We are putting both the Company's capital and our own shares behind our conviction in Cosmos Health. Resuming our buyback and committing our officers and Board to a 12-month lock-up send a clear message: our leadership is invested for the long term. With a strengthened balance sheet, record nine-month revenue and new growth engines, including our expanding subscription model, we believe Cosmos Health is well positioned, and we intend to stand behind that belief."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:
BDG Communications
[email protected]

SOURCE: Cosmos Health Inc.



View the original press release on ACCESS Newswire

W.Lane--TFWP